Prof Padmanee Sharma presents data from the CheckMate 025 trial at a press conference at ECC 2015. 

This open-label, phase III trial compared the PD-1 checkpoint inhibitor nivolumab against everolimus in the treatment of patients with metastatic renal cell carcinoma (mRCC).

Nivolumab significantly prolonged the primary endpoint of overall survival in patients whose disease has progressed after their first treatment. This is the only phase III trial to demonstrate such a survival advantage in previously treated mRCC versus standard therapy.

Read the news story here or watch the interview here.

See also comment from Martine Prof Piccart Jules Bordet Institute, Brussels, Belgium).